Cipla has allotted 4,576 equity shares under Employee Stock Option Scheme. Consequently, the issued, subscribed and paid-up share capital of the Company stands increased to Rs. 1,61,13,98,096 comprising of 80,56,99,048 equity shares of face value Rs.2/- each.

Powered by Capital Market - Live News

Cipla and Wellthy Therapeutics announced a partnership to offer a combination of pharmacotherapy and digital therapeutics for improved patient outcomes in the chronic therapies of diabetology and cardiology.

Under the agreement, a multi-lingual clinically-validated digital disease management platform will be made available to patients living with diabetes or cardiovascular diseases via doctors' clinics or co-packaging on select Cipla brands. The platform brings together behavioural science, real world clinical evidence and artificial intelligence to provide real time monitoring, coaching and advice to patients, and virtual clinical assistance to doctors.

This partnership is a result of Cipla's campaign, lnnoventia, which was envisioned as a first-of-its-kind challenge by an Indian pharmaceutical company to encourage innovation-led entrepreneurship and to harness disruptive ideas in healthcare to fulfil unmet patient needs.

Powered by Capital Market - Live News

Cipla announced that it has been awarded a share of the South African Government's National ARV tender for TEE (comprising tenofovir, emtricitabine and efavirenz) and TLD (a combination of tenofovir (TDF), lamivudine (3TC) and dolutegravir (DTG)). The contract is effective from 1 July 2019 and is valid for three years.

Powered by Capital Market - Live News

Net profit of Cipla declined 17.06% to Rs 332.20 crore in the quarter ended December 2018 as against Rs 400.51 crore during the previous quarter ended December 2017. Sales rose 1.87% to Rs 3906.20 crore in the quarter ended December 2018 as against Rs 3834.49 crore during the previous quarter ended December 2017.

Powered by Capital Market - Live News